Reuters logo
1 年前
BRIEF-Asterias biotherapeutics receives safety clearance to begin administering the highest dose of AST-OPC1 in the SCiStar phase 1/2a Clinical Trial in Cervical Spinal Cord Injury Patients
2016年8月31日 / 上午10点42分 / 1 年前

BRIEF-Asterias biotherapeutics receives safety clearance to begin administering the highest dose of AST-OPC1 in the SCiStar phase 1/2a Clinical Trial in Cervical Spinal Cord Injury Patients

Aug 31 (Reuters) - Asterias Biotherapeutics Inc

* Asterias Biotherapeutics receives safety clearance to begin administering the highest dose of AST-OPC1 in the SCiStar Phase 1/2a clinical trial in cervical spinal cord injury patients

* Data monitoring committee concludes that favorable safety profile observed in study supports plan for significant dose increase

* Concurrently, study is also proceeding with enrolling first cohort of 5-8 sensory incomplete cervical spinal cord injury patients

* Says "look forward to announcing six month follow up data from this 10 million cell cohort in January 2017" Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below